CN103520164B - 一种替卡格雷缓释制剂 - Google Patents
一种替卡格雷缓释制剂 Download PDFInfo
- Publication number
- CN103520164B CN103520164B CN201310522017.9A CN201310522017A CN103520164B CN 103520164 B CN103520164 B CN 103520164B CN 201310522017 A CN201310522017 A CN 201310522017A CN 103520164 B CN103520164 B CN 103520164B
- Authority
- CN
- China
- Prior art keywords
- slow
- magnesium stearate
- principal agent
- release
- adz6140
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 title claims abstract description 27
- 229960002528 ticagrelor Drugs 0.000 title claims abstract description 23
- 239000003405 delayed action preparation Substances 0.000 title abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 34
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 31
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 239000011248 coating agent Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims abstract description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 35
- 235000019359 magnesium stearate Nutrition 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 25
- 239000007939 sustained release tablet Substances 0.000 claims description 15
- 206010013786 Dry skin Diseases 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000007779 soft material Substances 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- 229960003943 hypromellose Drugs 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000005563 spheronization Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 4
- 229950005162 benexate Drugs 0.000 claims description 4
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 15
- 238000013268 sustained release Methods 0.000 abstract description 6
- 239000012730 sustained-release form Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 12
- 229920000858 Cyclodextrin Polymers 0.000 description 10
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 7
- 241001597008 Nomeidae Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940086777 brilinta Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310522017.9A CN103520164B (zh) | 2013-10-30 | 2013-10-30 | 一种替卡格雷缓释制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310522017.9A CN103520164B (zh) | 2013-10-30 | 2013-10-30 | 一种替卡格雷缓释制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103520164A CN103520164A (zh) | 2014-01-22 |
CN103520164B true CN103520164B (zh) | 2015-01-28 |
Family
ID=49922754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310522017.9A Active CN103520164B (zh) | 2013-10-30 | 2013-10-30 | 一种替卡格雷缓释制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103520164B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690502A (zh) * | 2013-12-31 | 2014-04-02 | 程刚 | 一种替卡格雷缓释制剂 |
CN104814923B (zh) * | 2014-08-21 | 2017-09-12 | 浙江海力生制药有限公司 | 一种盐酸坦洛新缓释制剂及其制备方法和其应用 |
CN105998026B (zh) * | 2015-03-26 | 2020-07-14 | 四川海思科制药有限公司 | 一种替卡格雷药物组合物及其制备方法 |
CN106074357B (zh) * | 2015-04-29 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 一种替格瑞洛或其可药用盐的制剂 |
CN105853385A (zh) * | 2016-03-31 | 2016-08-17 | 北京万全德众医药生物技术有限公司 | 一种替格瑞洛口崩缓释片及其制备方法 |
CN110711180B (zh) * | 2018-07-13 | 2022-03-29 | 武汉武药科技有限公司 | 一种替格瑞洛组合物及其制备方法 |
KR102244108B1 (ko) * | 2018-12-21 | 2021-04-23 | (주)휴온스 | 티카그렐러 또는 이의 염을 함유하는 서방형 약제학적 조성물 |
CN113018273A (zh) * | 2019-12-25 | 2021-06-25 | 上海宣泰医药科技股份有限公司 | 一种固体制剂及其制备方法和用途 |
CN111991362A (zh) * | 2020-09-07 | 2020-11-27 | 乐普(北京)医疗器械股份有限公司 | 一种替格瑞洛缓释片及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013084089A1 (en) * | 2011-12-09 | 2013-06-13 | Wockhardt Limited | Methods for treating cardiovascular disorder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780094B (zh) * | 2007-02-13 | 2011-08-17 | 昆明四创药业有限公司 | 雪胆素缓释制剂 |
CN102657629B (zh) * | 2012-05-14 | 2014-04-02 | 深圳市华力康生物医药有限公司 | 替卡格雷缓释片系统及其制备方法 |
-
2013
- 2013-10-30 CN CN201310522017.9A patent/CN103520164B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013084089A1 (en) * | 2011-12-09 | 2013-06-13 | Wockhardt Limited | Methods for treating cardiovascular disorder |
Also Published As
Publication number | Publication date |
---|---|
CN103520164A (zh) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103520164B (zh) | 一种替卡格雷缓释制剂 | |
CN102657629B (zh) | 替卡格雷缓释片系统及其制备方法 | |
CN101780073B (zh) | 非布司他分散片药物及其制备方法 | |
RU2616516C2 (ru) | Фармацевтическая композиция, содержащая олмесартана медоксомил и розувастатин или его соль | |
WO2020249001A1 (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
CN107249590A (zh) | 固体制剂 | |
CN101658505A (zh) | 非布索坦的缓释制剂及其制备方法 | |
CN104434805A (zh) | 一种替格瑞洛固体分散体及其制备方法 | |
CN103372014B (zh) | 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法 | |
CN1903182B (zh) | 小型化盐酸沙格雷酯经口给药制剂 | |
CN106309388A (zh) | 一种用于心衰治疗的药物组合物及其制备方法 | |
CN102114001A (zh) | 一种含有托伐普坦的口服固体制剂 | |
CN104873473A (zh) | 一种氯化钾缓释片及其制备方法 | |
CN103690502A (zh) | 一种替卡格雷缓释制剂 | |
CN107753455B (zh) | 一种含有咪达那新的片剂及其制备方法 | |
JP6368830B2 (ja) | 固形医薬組成物 | |
JP6434570B2 (ja) | 固形医薬組成物 | |
CN101972263B (zh) | 一种缬沙坦氢氯噻嗪药物组合物脂质体固体制剂 | |
CN106511291A (zh) | 一种盐酸阿考替胺缓释片剂及其制备方法 | |
CN101069687A (zh) | 恩替卡韦分散片及其制备方法 | |
CN101422441B (zh) | 尼美舒利缓释片及其制备方法 | |
CN101003536A (zh) | 恩替卡韦盐及其制备 | |
CN112057429B (zh) | 雷西纳德控释药物组合物 | |
CN102657615A (zh) | 一种长春胺缓释微丸制剂及其制备方法 | |
JP5491727B2 (ja) | リバビリン経口用錠剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING KANGLISHENG PHARMACEUTICAL TECHNOLOGY DEVE Free format text: FORMER OWNER: CHENG GANG Effective date: 20150610 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150610 Address after: 100176, No. 5, building 2, No. 22, Zhonghe street, Beijing economic and Technological Development Zone, Beijing Patentee after: BEIJING KANG LISHENG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. Address before: 100176 No. 22 Zhonghe street, Beijing economic and Technological Development Zone, Beijing Patentee before: Cheng Gang |